We lead innovation in whole blood analysis.
“Within minutes of sampling we can start the analysis using our unique ID.Flow technology. Understanding the interactions in circulating fresh whole blood we believe to be more physiologically relevant and imperative for better safety assessments, better supported INDs, and being in-line with the regulatory guidelines. ”
Alexander Kele, CEO
Immuneed’s mission is to accelerate the journey of bringing life-changing medicines to patients. We do so by providing technology-driven services to pharmaceutical and biotechnology companies worldwide.
Immuneed is a specialized service provider supporting drug developers with human-relevant immunological assessments for preclinical-stage molecules. With access to fresh human blood from local donors, Immuneed’s expert team performs comprehensive studies, analyzing how a drug impacts the adaptive and innate immune response—including immune cells, the complement system, cytokines, platelets, and immunoglobulins—and interprets the results. This approach provides drug developers with precise, human-relevant data to support safer, more effective drug development throughout the preclinical phase
Recently featured in Nature Communications, Immuneed’s innovative technology ID.Flow demonstrates its ability to detect responses that are undetectable with conventional in-vitro methods. Follow the link to access the Nature publication.
Next-generation whole blood analysis
Access to donors directly at our test site enables real-time whole-blood analysis. Immediate analysis of purely fresh blood has many advantages, including the possibility of evaluating drug effects on cellular functions and complex interconnected systems in the blood. This improves the relevance and translatability of nonclinical findings to clinical scenarios.
Partnerships
QUALIblood is a contract research organization specialized in blood investigations, providing bioanalytical support to pharmaceutical companies and research institutions engaged in drug development. With over than ten years of expertise in thrombosis and hemostasis, QUALIblood offers in-depth analysis of the coagulation activation, fibrinolysis system activation and hemolysis induced by drugs under development. Their expert team manages every aspect of the project, offering customized solutions from supplying necessary biological material to conducting assays and analyzing results. This comprehensive package provides essential, high-quality data necessary to assess the coagulation and hemocompatibility of a compound, a requirement to support safe and effective drug development during the preclinical stage.
CTC is a full-service CRO focusing on Phase I and Phase II clinical trials. CTC facilitates clinical and translational research by providing its customers with cost-effective advice and conducting and reporting clinical trials. They are capable of assuming full responsibility for the clinical development program, starting from the initial translation of preclinical data into the human setting and extending through Phase II.
CTC performs in-house clinical conduct at their FIH and Phase I-IV clinical research units in Sweden (6 units) and the Netherlands (1 unit). Their clinics work in close collaboration with their Clinical Operations, Biometrics, Pharmacovigilance and DMPK & Clinical Pharmacology departments to provide a true full-service option to their customers.
Who we are
We are a dedicated team driven by science, with a curious mindset and an entrepreneurial spirit. As a trusted partner in developing innovative drugs, we take great pride in being at the forefront of non-animal methods in pharmaceutical research. We deliver services that adhere to the 3Rs, which aim to reduce, refine, and replace animal studies in pharmaceutical research.
To continuously transform the way we work and operate and thereby improve our ability to innovate, expand, and meet our customers’ needs in the best way, we constantly ask ourselves;
- What can we improve?
- What can we do differently?
- How can we help our customers in the best way?
Feed
Category:Allpublicationsnewsinsights
No items available